4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Telomeres and telomerase in oncogenesis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Telomeres are located at the ends of chromosomes and protect them from degradation. Suppressing the activity of telomerase, a telomere-synthesizing enzyme, and maintaining short telomeres is a protective mechanism against cancer in humans. In most human somatic cells, the expression of telomerase reverse transcriptase (TERT) is repressed and telomerase activity is inhibited. This leads to the progressive shortening of telomeres and inhibition of cell growth in a process called replicative senescence. Most types of primary cancer exhibit telomerase activation, which allows uncontrolled cell proliferation. Previous research indicates that TERT activation also affects cancer development through activities other than the canonical function of mediating telomere elongation. Recent studies have improved the understanding of the structure and function of telomeres and telomerase as well as key mechanisms underlying the activation of TERT and its role in oncogenesis. These advances led to a search for drugs that inhibit telomerase as a target for cancer therapy. The present review article summarizes the organization and function of telomeres, their role in carcinogenesis, and advances in telomerase-targeted therapy.

          Related collections

          Most cited references101

          • Record: found
          • Abstract: found
          • Article: not found

          Alternative lengthening of telomeres: models, mechanisms and implications.

          Unlimited cellular proliferation depends on counteracting the telomere attrition that accompanies DNA replication. In human cancers this usually occurs through upregulation of telomerase activity, but in 10-15% of cancers - including some with particularly poor outcome - it is achieved through a mechanism known as alternative lengthening of telomeres (ALT). ALT, which is dependent on homologous recombination, is therefore an important target for cancer therapy. Although dissection of the mechanism or mechanisms of ALT has been challenging, recent advances have led to the identification of several genes that are required for ALT and the elucidation of the biological significance of some phenotypic markers of ALT. This has enabled development of a rapid assay of ALT activity levels and the construction of molecular models of ALT.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

            Nucleoside analogues have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with cancer or viral infections. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Here, we review new nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response rates and reduced side effects. We also highlight the different approaches used in the development of these drugs and the potential of personalized therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Systematic analysis of telomere length and somatic alterations in 31 cancer types

              Siyuan Zheng, Roel Verhaak and colleagues report an analysis of telomere lengths and somatic alterations in telomere-related pathways across 31 cancer types. Their study provides an overview of the molecular mechanisms driving TERT expression and activation of the ALT pathway, and identifies a subset of tumors with neither detectable TERT expression nor somatic alterations in ATRX or DAXX.
                Bookmark

                Author and article information

                Journal
                Oncol Lett
                Oncol Lett
                OL
                Oncology Letters
                D.A. Spandidos
                1792-1074
                1792-1082
                August 2020
                21 May 2020
                21 May 2020
                : 20
                : 2
                : 1015-1027
                Affiliations
                [1 ]Endocrinology Clinic, Holycross Cancer Center, 25-734 Kielce, Poland
                [2 ]Department of Molecular Diagnostics, Holycross Cancer Center, 25-734 Kielce, Poland
                [3 ]The Faculty of Health Sciences, Jan Kochanowski University, 25-319 Kielce, Poland
                [4 ]Oncology Clinic, Holycross Cancer Center, 25-734 Kielce, Poland
                Author notes
                Correspondence to: Dr Tomasz Trybek, Endocrinology Clinic, Holycross Cancer Center, Artwinskiego Street 3, 25-734 Kielce, Poland, E-mail: trytom1@ 123456tlen.pl
                Article
                OL-0-0-11659
                10.3892/ol.2020.11659
                7377093
                32724340
                e26a3086-209b-47d0-8119-4bdc05863190
                Copyright: © Trybek et al.

                This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

                History
                : 24 February 2020
                : 25 March 2020
                Categories
                Review

                Oncology & Radiotherapy
                telomerase,telomeres,cancer,telomerase reverse transcriptase,oncogenesis
                Oncology & Radiotherapy
                telomerase, telomeres, cancer, telomerase reverse transcriptase, oncogenesis

                Comments

                Comment on this article